AAD 7: Psoriasis: Screening for Psoriatic Arthritis
– National Quality Strategy Domain: Person and Caregiver Centered Experience and Outcomes

**2024 COLLECTION TYPE:**
QCDR MEASURE

**MEASURE TYPE:**
Process – High Priority

**DESCRIPTION:**
Percentage of patients with diagnosis of psoriasis who are screened for psoriatic arthritis at each visit.

High Priority Measure: Yes
Meaningful Measure Area: Management of Chronic Conditions
Risk-Adjusted: No
Inverse Measure: No
Proportional Measure: Yes
Continuous Variable Measure: No
Ratio Measure: No
Number of performance rates required for measure: 1st Performance Rate
Care Setting: Outpatient Services

**INSTRUCTIONS:**
This measure is to be reported at each visit for all denominator eligible patients during the reporting period. This measure may be reported by clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

**Measure Reporting via Registry**
ICD-10-CM diagnosis codes, CPT codes or HCPCS codes and patient demographics are used to identify patients who are included in the measure’s denominator. The listed numerator options are used to report the numerator of the measure.

The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

**DENOMINATOR:**
All patients with a diagnosis of psoriasis

**Denominator Criteria (Eligible Cases):**
Patients who meet each of the following criteria are included in the population:

- Patient aged 18 years or older at the start of the measurement period.
- Patient had an outpatient face to face encounter
- Patient had diagnosis of psoriasis

**CPT Codes for Identifying Eligible Face to Face Encounters:** 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99242, 99243, 99244, 99245, 99424, 99426, G0402

**Diagnosis Codes for Identifying Patients with Psoriasis:** L40.0, L40.1, L40.2, L40.3, L40.4, L40.8, L40.9

**NUMERATOR:**
Patients with psoriasis (any type) are screened* for psoriatic arthritis by documenting in the medical record the presence or absence of joint symptoms at each visit.

*Screening for psoriatic arthritis is defined as any one of the following:
• Documentation of inquiry about the presence or absence of joint symptoms including any of the following: morning stiffness, pain, redness, and/or swelling of joints.
• Documentation of a physical examination (e.g. visualization of joints, surrounding structures (entheses) and fingers/toes for dactylitis)
• Documentation of the use of a validated psoriatic arthritis screening instrument such as the PASE (Psoriatic Arthritis Screening and Evaluation), ToPAS (Toronto Psoriatic Arthritis Screening), PEST (Psoriasis Epidemiology Screening Tool), or EARp or EARp II (Early Arthritis for Psoriatic Patients).

Exclusions:
Patients with existing diagnosis of psoriatic arthritis

Diagnosis Codes for Identifying Patients with Psoriatic Arthritis
ICD-10 Codes L40.50, L40.51, L40.52, L40.53, L40.54, L40.59
Code Description Psoriatic arthropathy

RATIONALE:
The prevalence of psoriatic arthritis (PsA) in the general population of the United States has been estimated to be between 0.1% to 0.25%. Among those with psoriasis, the prevalence of PsA is approximately 10%. Dermatologists are strongly encouraged to actively seek signs and symptoms of PsA at each visit. If PsA is diagnosed, treatment should be initiated to alleviate signs and symptoms of PsA, prevent structural damage, and maximize quality of life (QOL). Dermatologists uncomfortable or untrained in evaluating or treating patients with PsA should refer such patients to rheumatologists.

CLINICAL RECOMMENDATION STATEMENTS:
Patients with psoriasis are at an increased risk of having psoriatic arthritis. This measure seeks for dermatologists to actively assess for psoriatic arthritis to relieve symptoms, prevent structural damage, and improve quality of life.

COPYRIGHT:
©American Academy of Dermatology/Association. All rights reserved.

The American Academy of Dermatology and the American Academy of Dermatology Association (collectively AAD/A) own all right, title, and interest in this quality measure. This quality measure is provided solely for the benefit of AAD/A and its members for the purposes specified herein and for other AAD/A purposes. It may not be used by other parties except with prior written approval of the AAD/A.